T529-15D3-2E5-4G12-1A7細胞
是否是腫瘤細胞： 0
物種來源： 小鼠
細胞形態： **樣
**類型： IgG1; kappa light chain
數量： 大量
運輸方式： 凍存運輸
ATCC Number： HB-10501?
T529-15D3-2E5-4G12-1A7細胞生長狀態： 懸浮生長
Designations: T529-15D3-2E5-4G12-1A7 [1A7, CTCC 10753]
Depositors: Chiron Corp.
Isotype: IgG1; kappa light chain
Biosafety Level: 1
Shipped: frozen
Medium & Serum: See Propagation
Growth Properties: suspension
Organism: Mus musculus (B cell); T529-15D3-2E5-4G12-1A7細胞Mus musculus (myeloma) deposited as mouse (B cell); mouse (myeloma)
Morphology: lymphoblast
Source: Cell Type: hybridoma: B lymphocyte;
Cellular Products: immunoglobulin; monoclonal antibody; against the human Fc gamma receptor III (hFc gamma IIIR) and the multi-drug resistance antigen, P-glycoprotein
Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Comments: T529-15D3-2E5-4G12-1A7細胞The hybrid hybridoma cell lines 1B7 (ATCC HB-10500) and 1A7 (ATCC HB-10501) were formed by the fusion of the 15D3 (ATCC HB-11342) and 3G8 hybridoma cell lines. [56195]
The murine hybridoma 15D3 recognizes the human multi-drug resistance antigen, P-glycoprotein.
The murine hybridoma 3G8 recognizes the human Fc gamma receptor III.
The hybrid hybridoma cell lines 1B7 and 1A7 produce bispecific antibodies that recognize both the human Fc gamma receptor III (hFc gamma IIIR) and the multi-drug resistance antigen, P-glycoprotein. [56196]
The 1B7 and the 1A7 antibodies are capable of binding to both the Fc receptors of cytotoxic cells, and tumor cells exhibiting multi-drug resistance phenotype, wherein the tumor cells over-express P-glycoproteins as compared to normal cells. [56196]
These bispecific antibodies are useful in killing cancer cells. [56196]
Propagation: ATCC complete growth medium: Iscove's modified Dulbecco's medium with 4 mM L-glutamine adjusted to contain 1.5 g/L sodium bicarbonate supplemented with 1% OPI (0.15 mg/ml oxaloacetate, 0.05 mg/ml pyruvate, 0.0082 mg/ml bovine insulin), 90%; heat-inactivated fetal bovine serum, 10%
Temperature: 37.0°C
Subculturing: Medium Renewal: T529-15D3-2E5-4G12-1A7細胞Add fresh medium every 2 to 3 days (depending on cell density)
Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 1 to 2 X 10 exp5 viable cells/ml.
Maintain cell density between 1 X 10 exp5 and 1 X 10 exp6 viable cells/ml.
Preservation: culture medium 95%; DMSO, 5%
Related Products: Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2005
parental cell line:ATCC HB-11342
References: 56193: Ring D, Shi TX. Monoclonal anti-multiple drug resistance antibody, methods of production and uses thereof. US Patent 6,143,873 dated Nov 7 2000
56195: Ring D, Shi TX. Bispecific antibodies, methods of production and uses thereof. US Patent 5,959,084 dated Sep 28 1999
56196: Ring D, Shi TX. Bispecific antibodies, methods of production and uses thereof. US Patent 6,106,833 dated Aug 22 2000
